Bunin Laboratory for Pediatric Oncology Transplant Research

Ongoing clinical studies in the Bunin Lab are focused on providing better medical outcomes for children who receive bone marrow transplants as a cancer treatment. Researchers in the Bunin program have developed unique transplantation protocols to reduce the risk of graft vs. host disease (GVHD) with unrelated or partially-matched donors. This increases the size of potential donor pools for children who require bone marrow transplants to treat cancer.

Dr. Bunin is involed in other clinical studies that evaluating the use of sirolimus to treat patients with relapsed leukemia and lymphoma after bone marrow transplants. Researchers have demonstrated that activation of donor cells using a unique activation process can have potent anti-cancer effects on children with relapsed leukemia or lymphoma.

Future studies will continue to focus on modifying and developing blood and bone marrow transplantation methods that improve medical outcomes and decrease the risks and toxicities associated with pediatric cancer therapies.